Weaver Consulting Group’s AstraZeneca AZN Stock Holding History

Weaver Consulting Group’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-99	Closed	-$11K	–	198
2020 Q3	$11K	Buy	+99	New	+$11K	0.01%	533

Other funds holding AZN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Weaver Consulting Group's AZN Position: Q4 2020 in Review

Weaver Consulting Group sold out of AstraZeneca (AZN) in Q4 2020, closing a stake of 99 shares — an estimated $11K sold.

Weaver Consulting Group first reported a position in AZN in Q3 2020 and held it in 1 quarter. The position peaked at $11K in Q3 2020. 787 funds tracked by Wall St. Rank hold AZN as of Q4 2020.

Weaver Consulting Group reported no remaining AstraZeneca position as of Q4 2020 after selling out during the quarter.
Weaver Consulting Group sold 99 AstraZeneca shares in Q4 2020, an estimated $11K.
Weaver Consulting Group first reported a position in AstraZeneca in Q3 2020 and held it in 1 quarter.
Weaver Consulting Group's AstraZeneca position peaked at $11K in Q3 2020.
787 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2020.

Based on Weaver Consulting Group's 13F filing for Q4 2020, filed 29 Jan 2021.